Loading...

SOHO 2026 Annual Meeting

This website and third-party tools we use rely on cookies for the best user experience. By selecting "I agree", you agree to cookie usage as described in our Privacy Policy.

1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

ePostersLive by SciGen Technologies S.A. All rights reserved.

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Home Posters by Code Posters by Title Authors Affiliations Topics Sessions Videos Audios Previous meetings

Topics

Select Topic

Showing 55 results for "Chronic Myeloid Leukemia (CML)".

Thumbnail for Reduction in Thyroid Volume in Patients With Chronic Myeloid Leukemia After Imatinib Treatment: A Prospective Cohort Study

CML - 029

Reduction in Thyroid Volume in Patients With Chronic Myeloid Leukemia After Imatinib Treatment: A Prospective Cohort Study

Ibrahim Ahmed

Poster Presenter: Ibrahim Ahmed

Thumbnail for Role of MicroRNA as a Key Epigenetic Regulator in Promoting Nuclear Reprogramming in an Adult Egyptian Chronic Myeloid Leukemia Patient

CML - 053

Role of MicroRNA as a Key Epigenetic Regulator in Promoting Nuclear Reprogramming in an Adult Egyptian Chronic Myeloid Leukemia Patient

Haydi Mohamed

Poster Presenter: Haydi Mohamed

Previous 1 2 3 4...7 Next

Copyright © 2015-2026, ePostersLive® SciGen is a registered trademark of SciGen Technologies S.A. Patent pending.

CML - 090

Real-World Data on Clinical Profile, Treatment Strategies, and Feto-Maternal Outcomes of Pregnancies Among Patients With Chronic Myeloid Leukemia in a Resource-Constrained Setting: A 5-Year Single-Center Retrospective Cohort Study

Caryn Louise Gutierrez

Poster Presenter: Caryn Louise Gutierrez

Thumbnail for Efficacy and Safety of a Pakistan-Manufactured Generic Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: A Multicenter Phase 4 Study

CML - 1023

Efficacy and Safety of a Pakistan-Manufactured Generic Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: A Multicenter Phase 4 Study

Zeba Aziz

Poster Presenter: Zeba Aziz

Thumbnail for ASC4FIRST Week (Wk) 144 Analysis: Continued Superior Efficacy and Favorable Safety of Asciminib (ASC) vs Investigator-Selected Tyrosine Kinase Inhibitors (IS-TKIs) in Newly Diagnosed (ND) Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

CML - 1050

ASC4FIRST Week (Wk) 144 Analysis: Continued Superior Efficacy and Favorable Safety of Asciminib (ASC) vs Investigator-Selected Tyrosine Kinase Inhibitors (IS-TKIs) in Newly Diagnosed (ND) Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Ghayas Issa

Poster Presenter: Ghayas Issa

Thumbnail for Genetic Mutations Detected in Adult Patients Diagnosed With Chronic Myeloid Leukemia (CML): 24 Years of Experience in a Public Hospital in Guatemala

CML - 1071

Genetic Mutations Detected in Adult Patients Diagnosed With Chronic Myeloid Leukemia (CML): 24 Years of Experience in a Public Hospital in Guatemala

Ann Margareth Wagner-Nitsch

Poster Presenter: Ann Margareth Wagner-Nitsch

Thumbnail for Digital PCR versus qPCR for BCR::ABL1 Monitoring and Treatment-Free Remission Prediction in Chronic Myeloid Leukemia: A Systematic Review and Meta-Analysis

CML - 1127

Digital PCR versus qPCR for BCR::ABL1 Monitoring and Treatment-Free Remission Prediction in Chronic Myeloid Leukemia: A Systematic Review and Meta-Analysis

Amal Paul

Poster Presenter: Amal Paul

Thumbnail for Sequential Enumeration of CD26+ Leukemic Stem Cells and Its Correlation With BCR::ABL1 Transcript Levels in Chronic Myeloid Leukemia at Diagnosis and During Tyrosine Kinase Inhibitor Therapy

CML - 1129

Sequential Enumeration of CD26+ Leukemic Stem Cells and Its Correlation With BCR::ABL1 Transcript Levels in Chronic Myeloid Leukemia at Diagnosis and During Tyrosine Kinase Inhibitor Therapy

Praveen Sharma

Poster Presenter: Praveen Sharma

Thumbnail for Efficacy and Safety of Asciminib Dose Escalation in Patients with Chronic Myeloid Leukemia (CML) without Optimal Response to the Standard Dose

CML - 1134

Efficacy and Safety of Asciminib Dose Escalation in Patients with Chronic Myeloid Leukemia (CML) without Optimal Response to the Standard Dose

Elza Lomaia

Poster Presenter: Elza Lomaia

ePosters in

Topics Sessions

Myelodysplastic Syndromes (MDS)(71)Myeloproliferative Neoplasms (MPN)(102)T-Cell Lymphoma (TCL)(28)

Previous 1 2 Next

Sponsors